Market capitalization | $174.63m |
Enterprise Value | $138.40m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 6.84 |
P/S ratio (TTM) P/S ratio | 8.64 |
P/B ratio (TTM) P/B ratio | 5.38 |
Revenue growth (TTM) Revenue growth | 8.22% |
Revenue (TTM) Revenue | $20.22m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
5 Analysts have issued a MediWound Ltd. forecast:
5 Analysts have issued a MediWound Ltd. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 20 20 |
8%
8%
|
|
Gross Profit | 2.63 2.63 |
27%
27%
|
|
EBITDA | -18 -18 |
26%
26%
|
EBIT (Operating Income) EBIT | -19 -19 |
25%
25%
|
Net Profit | -30 -30 |
350%
350%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.
Head office | Israel |
CEO | Ofer Gonen |
Employees | 111 |
Founded | 2000 |
Website | www.mediwound.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.